Cas:602316-03-0 N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide manufacturer & supplier

Chemical Name:N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide

CAS.NO:602316-03-0

Synonyms:N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide

Molecular Formula:C₁₆H₁₉NO₃S

Molecular Weight:305.39196

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide Use and application,N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide technical grade,usp/ep/jp grade.

Related News: Last month, Emergent Chief Executive Robert Kramer said it was his understanding that there are 100 million doses of J&J’s vaccine ready for FDA review and that regulators had begun the review process. N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide manufacturer Adding Darzalex to Bristol Myers Squibb’s Revlimid and steroid dexamethasone (Rd) could slash the risk of death by 32% in newly diagnosed multiple myeloma patients ineligible to receive stem cell transplants, J&J reported at the European Hematology Association’s virtual congress. N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide supplier It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing. N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide vendor It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing. N-(1-(3-Methoxyphenyl)ethyl)-4-MethylbenzenesulfonaMide factory Factors that have a significant impact on the sales volume of APIs come from the production side, which mainly includes costs and processes.